非小细胞肺癌的新辅助疗法:基础,希望和挑战
Sukumar Kalvapudi1, Yeshwanth Vedire1, Sai Yendamuri1,2
1Department of Thoracic Surgery, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States.
Frontiers in oncology
|December 25, 2023
概括
新辅助疗法在早期非小细胞肺癌 (NSCLC) 中表现有前途,通过改善结果并使手术成为可能. 需要进一步的研究来克服挑战,并确定其在NSCLC治疗中的作用.
科学领域:
- 在瘤学瘤学.
- 胸部外科手术 胸部外科手术
- 医学瘤学 医学瘤学
背景情况:
- 早期非小细胞肺癌 (NSCLC) 的存活率尽管采用了标准的手术和辅助治疗,但仍然不够理想.
- 新辅助疗法正在成为改善结局和促进NSCLC治疗切除的策略.
- 本综述侧重于新辅助疗法在NSCLC治疗中的当前和不断发展的应用.
研究的目的:
- 总结一下NSCLC中新辅助疗法的当前情况.
- 讨论新兴的新辅助药策略及其对临床和病理结果的影响.
- 突出在NSCLC中新辅助疗法的挑战和未来方向.
主要方法:
- 我们对PubMed.gov和ClinicalTrials.gov进行了全面的文献搜索.
- 确定和审查了与NSCLC新辅助疗法相关的研究和临床试验.
- 107篇文章和17项正在进行的试验被选中进行分析.
主要成果:
- 新辅助疗法表现出与辅助疗法相比的或更高的安全性和有效性.
- 它有助于降低疾病的发展阶段,并通过减少瘤负担和解决微转移而实现治愈性外科切除.
- 新型药物 (化疗,免疫疗法,向疗法) 正在研究中,导致个性化治疗方法.
结论:
- 新辅助疗法是NSCLC的一个有前途的方法,具有已确定的疗效和MPR和pCR等替代终点的发展.
- 挑战包括由于不良事件或耐药性而导致手术的潜在延迟,以及需要对预测标志物的强有力的验证.
- 大规模的随机对照试验对于解决这些问题和进一步将新辅助疗法纳入标准NSCLC护理至关重要.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
06:03Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
17.0K
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K